Summary of Study ST002696

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001668. The data can be accessed directly via it's Project DOI: 10.21228/M83H7N This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002696
Study TitleATP10A promotes endothelial cell insulin sensitivity and protects against female-specific dyslipidemia
Study TypeMS Untargeted Lipidomics
Study SummaryEndothelial dysfunction is strongly associated with metabolic and cardiovascular disease but how genetic and environmental factors intersect to promote disease progression remains elusive. Genetic association studies have linked ATP10A and closely related type IV P-type ATPases (P4-ATPases) to insulin resistance and vascular complications, such as atherosclerosis. Here, we generated Atp10A knockout mice and show that Atp10A deficiency results in female-specific dyslipidemia, independent of diet-induced obesity, characterized by elevated plasma triglycerides, free fatty acids and cholesterol, and altered HDL properties. We also observed increased circulating levels of several sphingolipid species and reduced levels of eicosanoids and bile acids. The Atp10A-/- mice also display hepatic insulin resistance without perturbations to whole-body glucose homeostasis. ATP10A is expressed in vascular and lymphatic endothelial cells, where reduced expression causes hyperactive insulin receptor signaling at basal insulin levels and an inability to properly respond to added insulin. This unique form of insulin resistance suggests that ATP10A promotes insulin receptor desensitization to maintain endothelial cell insulin sensitivity. These findings are clinically relevant because therapeutics that enhance ATP10A expression could improve vascular health and lipid metabolic profiles.
Vanderbilt University
LaboratoryCenter for Innovative Technology
Last NameMay
First NameJody
Address2301 Vanderbilt Place, Nashville, TN, 37235, USA
Submit Date2023-04-20
Num Groups2
Total Subjects10
Raw Data AvailableYes
Raw Data File Type(s)d, mzML
Analysis Type DetailLC-MS
Release Date2023-05-24
Release Version1
Jody May Jody May application/zip

Select appropriate tab below to view additional metadata details:

Combined analysis:

Analysis ID AN004369 AN004370
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Agilent 6560 Agilent 6560
Column Agilent ZORBAX RRHD Extend-C18 (50 x 2.1mm,1.8um) Agilent ZORBAX RRHD Extend-C18 (50 x 2.1mm,1.8um)
MS instrument type QTOF QTOF
MS instrument name Agilent 6560 Ion Mobility Agilent 6560 Ion Mobility
Units Ion Abundances Ion Abundances


MS ID:MS004116
Analysis ID:AN004369
Instrument Name:Agilent 6560 Ion Mobility
Instrument Type:QTOF
MS Comments:Data alignment and biostatical analysis was performed using Progenesis QI (Waters).
MS ID:MS004117
Analysis ID:AN004370
Instrument Name:Agilent 6560 Ion Mobility
Instrument Type:QTOF
MS Comments:Data alignment and biostatical analysis was performed using Progenesis QI (Waters).